OverviewSuggest Edit

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

TypePublic
Founded1992
HQPlanegg, DE
Websitemorphosys.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Jul 2021)609
Share Price (Nov 2021)€38.6(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at MorphoSys

Jean-Paul Kress

Jean-Paul Kress

Chief Executive Officer
Anja Hanisch

Anja Hanisch

Senior Director Licensing
Malte Peters

Malte Peters

Chief Research and Development Officer
Charlotte Lohmann

Charlotte Lohmann

SVP General Counsel
Sung Lee

Sung Lee

Chief Financial Officer
Monika Bähner

Monika Bähner

Senior Director Search & Evaluation
Show more

MorphoSys Office Locations

MorphoSys has offices in Planegg and Boston
Planegg, DE (HQ)
Semmelweisstraße 7
Boston, MA, US
470 Atlantic Ave #1401
Show all (2)

MorphoSys Financials and Metrics

MorphoSys Revenue

Market capitalization (10-Nov-2021)

1.3b

Closing stock price (10-Nov-2021)

38.6
MorphoSys's current market capitalization is €1.3 b.
Show all financial metrics

MorphoSys Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

MorphoSys Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

MorphoSys Online and Social Media Presence

Embed Graph

MorphoSys News and Updates

MorphoSys to buy Constellation Pharma for $1.7 billion; Constellation's stock soars 61%

Shares of MorphoSys AG ADR were down 8.9% in premarket trading on Wednesday after the company announced a $1.7 billion acquisition of Constellation Pharmaceuticals Inc. . Constellation's stock soared 61.3% in premarket trade. The boards of both companies have approved the deal, which is expected to…

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST).…

Chief scientist quits at Germany's Morphosys ahead of product launch

Morphosys' chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch.

I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

SHANGHAI, Oct. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases and German...

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 19, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime...
Show more

MorphoSys Blogs

Products Text EN

FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) On July 31, 2020, Monjuvi® (tafasitamab-cxix) received accelerated approval in the United States from the Food…

Partnerships on discovery stage compounds, targets and technologies

Partnerships on discovery stage compounds, targets and technologies MorphoSys’ success is deeply rooted in the appreciation of science. We have entered various collaborations with pharmaceutical companies, biotechs and academics to bring in and further develop novel targets, differentiat…

Strengthening our development portfolio

Strengthening our development portfolio Backed by a strong financial position with the mandate to invest in drug development, we are striving to build one of the most valuable pipelines of innovative therapies in the industry. In line with this strategic goal, our partnering activities c…

Company Intro

In July 2020, the U.S. Food and Drug Administration granted accelerated approval of Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. We are very proud that we could bring a new treatment option to thousands of patients and are a c…

Science Antibodies that target GPCRs

The G protein-coupled receptor (GPCR) superfamily is the largest and single most important family of drug targets (~800 members) in the human body. These proteins are active in just about every organ system and present a wide range of opportunities as therapeutic targets in areas includi…

Science Inflammatory and autoimmune diseases

Both autoimmune and inflammatory diseases arise through uncharacteristic reactions of the human immune system. In autoimmunity, the patient's immune system is activated against the body's own proteins. In chronic inflammatory diseases, neutrophils and other leukocytes are constitutively …
Show more

MorphoSys Frequently Asked Questions

  • When was MorphoSys founded?

    MorphoSys was founded in 1992.

  • Who are MorphoSys key executives?

    MorphoSys's key executives are Jean-Paul Kress, Anja Hanisch and Malte Peters.

  • How many employees does MorphoSys have?

    MorphoSys has 609 employees.

  • Who are MorphoSys competitors?

    Competitors of MorphoSys include Medicalsystem Biotechnology, Diater and Ajinomoto Althea.

  • Where is MorphoSys headquarters?

    MorphoSys headquarters is located at Semmelweisstraße 7, Planegg.

  • Where are MorphoSys offices?

    MorphoSys has offices in Planegg and Boston.

  • How many offices does MorphoSys have?

    MorphoSys has 2 offices.